BOTHELL, Wash.--(BUSINESS WIRE)--Helix BioMedix, Inc. (OTCBB: HXBM), a developer of bioactive peptides, today announced financial results for the third quarter ended September 30, 2007.
Revenue for the three months ended September 30, 2007, was approximately $159,400, compared to approximately $18,800 for the comparable period in 2006. For the nine months ended September 30, 2007, revenue was approximately $358,400, compared to approximately $66,900 for the comparable period in 2006.
